HYPERION DEFI, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
HYPERION DEFI, INC. (HYPD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $10.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-09-30 was $0.40.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-06-30 was $0.44, a 78.43% decline year-over-year.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.33, a 17.39% decline year-over-year.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-06-30 was $2.04.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $10.00, a 84.13% decline from fiscal 2024.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $63.00, a 52.27% decline from fiscal 2023.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $132.00, a 8150.00% increase from fiscal 2022.
- HYPERION DEFI, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.60, a 70.32% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $10.00 10-K · filed 2026-03-30 | ||||||
| 2025-09-30 | $11.28 10-Q · filed 2025-11-14 | ||||||
| 2024-12-31 | $63.00 10-K · filed 2026-03-30 | ||||||
| 2024-09-30 | $0.40 10-Q · filed 2024-11-12 | $0.79 10-Q · filed 2024-11-12 | |||||
| 2024-06-30 | $0.44 10-Q · filed 2024-08-14 | $0.84 10-Q · filed 2024-08-14 | |||||
| 2024-03-31 | $1.33 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | $132.00 10-K · filed 2025-04-15 | $1.65 10-K · filed 2024-03-18 | |||||
| 2023-09-30 | $1.70 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | $2.04 10-Q · filed 2024-08-14 | $1.78 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | $1.61 10-Q · filed 2024-05-15 | ||||||
| 2022-12-31 | $1.60 10-K · filed 2024-03-18 | ||||||
| 2021-12-31 | $5.39 10-K · filed 2023-03-31 | ||||||
| 2021-03-31 | $3.82 10-Q · filed 2021-05-14 | ||||||
| 2020-12-31 | $3.01 10-K · filed 2022-03-30 | ||||||
| 2020-03-31 | $4.13 10-Q · filed 2021-05-14 | ||||||
| 2019-12-31 | $3.10 10-K · filed 2021-03-30 | ||||||
| 2019-06-30 | $2.74 10-Q · filed 2019-08-13 | ||||||
| 2019-03-31 | $2.74 10-Q · filed 2019-05-14 | ||||||
| 2019-01-14 | $2.74 10-K · filed 2020-03-30 | ||||||
| 2018-12-31 | $6.39 10-K · filed 2020-03-30 | ||||||
| 2018-09-30 | $5.66 10-Q · filed 2019-11-13 | $6.95 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | $8.72 10-Q · filed 2018-08-14 | ||||||
| 2018-04-16 | $8.72 10-K · filed 2020-03-30 | ||||||
| 2017-12-31 | $1.77 10-K · filed 2019-03-27 | $1.95 10-K · filed 2018-04-02 | |||||
| 2017-09-30 | $1.84 10-Q · filed 2018-11-13 | $1.84 10-Q · filed 2018-11-13 | |||||
| 2017-07-07 | $1.95 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |